Market Place
Sourcing Support
Genmab Completes Tender Offer For Merus N.V. Shares
12 Dec 2025 //
PHARMIWEB
Genmab Initiates Tender Offer For Merus N.V. Shares
21 Oct 2025 //
GLOBENEWSWIRE
Genmab Acquires Merus, Boosts Late-Stage Pipeline
30 Sep 2025 //
BUSINESSWIRE
Merus to present at Canaccord Genuity 45th Annual Conference
06 Aug 2025 //
GLOBENEWSWIRE
Merus Announces Q2 2025 Financial Results and Business Update
05 Aug 2025 //
GLOBENEWSWIRE
Merus N.V. Announces Pricing of Public Offering of Common Shares
04 Jun 2025 //
GLOBENEWSWIRE
Merus N.V. Announces Proposed Public Offering of Common Shares
03 Jun 2025 //
GLOBENEWSWIRE
Merus To Present At Citi’s 2025 Virtual Oncology Leadership Summit
13 Feb 2025 //
GLOBENEWSWIRE
Merus to Present at Upcoming Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Merus Reports Q3 2024 Financial Results & Business Update
31 Oct 2024 //
GLOBENEWSWIRE
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
06 Aug 2024 //
GLOBENEWSWIRE
Merus Reports Q2 2024 Results And Provides Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Merus Doses First Patient In Phase 3 Petosemtamab Trial For HNSCC
24 Jul 2024 //
GLOBENEWSWIRE
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
01 Jul 2024 //
GLOBENEWSWIRE
Merus Announces Pricing of Upsized Public Offering of Common Shares
29 May 2024 //
GLOBENEWSWIRE
Merus N.V. Announces Proposed Public Offering of Common Shares
28 May 2024 //
GLOBENEWSWIRE
Merus Presents Preclinical Data at the AACR
08 Apr 2024 //
GLOBENEWSWIRE
Merus to Participate in a Fireside Chat at the 23rd Needham Virtual Conference
03 Apr 2024 //
GLOBENEWSWIRE
Gilead bets $1.5B-plus on Merus` trispecifc T-cell engagers
06 Mar 2024 //
FIERCE BIOTECH
Merus Announces Publication of an Abstract for Presentation
05 Mar 2024 //
GLOBENEWSWIRE
Merus to Participate in Fireside Chat at the Leerink Partners Global Conference
04 Mar 2024 //
PRESS RELEASE
Merus shares dip as lung cancer data reveal 3 patient deaths
05 Dec 2023 //
FIERCE BIOTECH
Merus Announces Financial Results for the Third Quarter 2023
02 Nov 2023 //
GLOBENEWSWIRE
Merus to Participate in Upcoming Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Merus™ Zeno Data Continues to Demonstrate Durable Responses in NRG1+ Cancer
23 Oct 2023 //
GLOBENEWSWIRE
Merus` NRG1+ drug responses edge up in tough pancreatic cancer
23 Oct 2023 //
FIERCE BIOTECH
Merus Announces Abstracts Accepted for Presentation at ESMO Asia Congress 2023
06 Oct 2023 //
GLOBENEWSWIRE
Merus to Participate in Upcoming Investor Conferences
31 Aug 2023 //
GLOBENEWSWIRE
Merus N.V. Announces Proposed Public Offering of Common Shares
09 Aug 2023 //
GLOBENEWSWIRE
Merus Announces Pricing of Public Offering of Common Shares
09 Aug 2023 //
GLOBENEWSWIRE
Merus Announces Financial Results for the Second Quarter 2023
07 Aug 2023 //
GLOBENEWSWIRE
Merus Appoints Life Sciences Strategic & Financial Veteran Greg Perry as CFO
15 Jun 2023 //
GLOBENEWSWIRE
Merus to Participate in a Fireside Chat at Jefferies Healthcare Conference 2023
31 May 2023 //
GLOBENEWSWIRE
Merus Announces Financial Results for the 1Q 2023 and Provides Business Update
04 May 2023 //
GLOBENEWSWIRE
Merus Announces Financial Results for Q4 and Full Year 2022
28 Feb 2023 //
GLOBENEWSWIRE
Merus to Participate in Upcoming Investor Conferences
01 Feb 2023 //
GLOBENEWSWIRE
CORRECTING and REPLACING --Merus Provides 2023 Outlook
09 Jan 2023 //
GLOBENEWSWIRE
Merus Provides 2023 Outlook
08 Jan 2023 //
GLOBENEWSWIRE
Merus Announces Financial Results for the Third Quarter
03 Nov 2022 //
GLOBENEWSWIRE
Merus Presents First in Human Data on MCLA-129 at ENA Symposium
26 Oct 2022 //
GLOBENEWSWIRE
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC
12 Oct 2022 //
GLOBENEWSWIRE
Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR
07 Sep 2022 //
GLOBENEWSWIRE
Merus to Participate in a Panel Discussion at Citi`s 17th Annual BioPharma
01 Sep 2022 //
GLOBENEWSWIRE
Merus Announces Financial Results for the Second Quarter
08 Aug 2022 //
GLOBENEWSWIRE
Merus looks to beat Elevation to NRG1+ summit as BLA filing approaches
06 Jun 2022 //
ENDPTS
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
03 Jun 2022 //
GLOBENEWSWIRE
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1+ Cancer at ASCO
26 May 2022 //
GLOBENEWSWIRE
Merus to Present at the H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Merus Announces Financial Results for the First Quarter 2022
09 May 2022 //
GLOBENEWSWIRE
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 ASCO
27 Apr 2022 //
GLOBENEWSWIRE
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158)
25 Apr 2022 //
GLOBENEWSWIRE
Merus Presents Preclinical Data on MCLA-129 at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Merus to Participate in a Fireside Chat at the 21st Needham Conference
06 Apr 2022 //
GLOBENEWSWIRE
Merus says Publication of Abstract on MCLA-129 at the AACR
08 Mar 2022 //
GLOBENEWSWIRE
Merus Announces Financial Results for the Q4 and Full Year 2021
28 Feb 2022 //
GLOBENEWSWIRE
Merus appoints Shannon Campbell as CCO and regains WW rights to MCLA-145
26 Jan 2022 //
GLOBENEWSWIRE
Incyte Provides Update on Parsaclisib and MCLA-145
25 Jan 2022 //
BUSINESSWIRE
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine
10 Dec 2021 //
GLOBENEWSWIRE
Merus to Participate in a Fireside Chat at the Jefferies London Conference
10 Nov 2021 //
GLOBENEWSWIRE
